Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epstein-barr virus dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- Shenzhen People's Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
The Epstein-Barr virus (EBV) dendritic cell vaccine developed by Shenzhen People's Hospital is an autologous cell-based immunotherapy designed to treat nasopharyngeal carcinoma (NPC), a malignancy strongly associated with EBV infection. The vaccine is produced by isolating a patient's peripheral blood mononuclear cells, differentiating them into dendritic cells (DCs), and loading them with EBV-specific antigens, such as Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2). Once re-administered to the patient via intranodal injection, these matured and pulsed DCs present the viral antigens to the immune system, specifically activating EBV-specific cytotoxic T lymphocytes (CTLs) to recognize and eliminate tumor cells expressing these viral proteins. This approach aims to overcome the immune evasion typically seen in EBV-associated tumors by providing a potent stimulus for a targeted cellular immune response.
- Other names
- EBV-DC vaccineEBV-specific dendritic cell vaccineEpstein-Barr virus-specific dendritic cell vaccineautologous EBV-antigen pulsed dendritic cell vaccine
02
Targets
LMP1 (Epstein-Barr virus latent membrane protein 1)LMP2A (Latent membrane protein 2A)
Beyond the preview
Go deeper on epstein-barr virus dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epstein-barr virus dendritic cell vaccine.